Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | HTR6 | P50406 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554700 | 1.00 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8559799 | 1.00 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8559706 | 1.00 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8559095 | 1.00 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL1463660 | 0.98 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8556091 | 0.95 | HTR1A (0.73) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL1703893 | 0.91 | MEN1 (0.67) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8556230 | 0.90 | GRM5 (0.66) | HTR1ADRD2HTR6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27657032 | 0.89 | GRM5 (0.64) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL14028451 | 0.87 | HTR1A (0.79) | HTR1ADRD2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| EP-2440527-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | Topo Target A/S (DK) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142735-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TOPOTARGET A/S (DK) | 2010-12-16 | — | — | WO | disclosed |
| EP-0575954-B1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI SRL (IT) | 1998-09-02 | — | — | EP | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | HTR1A 1298/4885DRD2 2706/4885HTR6 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.